Phase 3 Trials Retatrutides Phase 3 program tests it for obesity, type 2 diabetes, and related metabolic disorders in diverse patient populations
Wegovy (semaglutide) is an FDA-approved medication for chronic weight management in adults with obesity or are overweight who also have weight-related medical conditions
The FDA recommends only purchasing from a state-licensed pharmacy to protect yourself
Compounded semaglutide at $199/month provides the best combination of effectiveness and affordability, producing 10-15% average weight loss at 85% less cost than brand-name Wegovy ($1,349/month)
These signals tell your brain that food has arrived, instruct the pancreas to prepare insulin, and help regulate how quickly nutrients enter the bloodstream
Most recently, there are new indications for chronic kidney disease and sleep apnea